Evidence map›Paper›PMID 31747918›Full record

ArticleBMC nephrology2019

Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD.

Keith C Norris, O Kenrik Duru, Radica Z Alicic, Kenn B Daratha, Susanne B Nicholas, Sterling M McPherson, Douglas S Bell, Jenny I Shen, Cami R Jones, Tannaz Moin and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. A Real-World Cohort Study of the Risks of Kidney Failure and Death in Diabetes.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Meeting People Where They Are: Improving Diabetes Care and Outcomes Through Education and Collaboration.Diabetes spectrum : a publication of the American Diabetes Association · 2025
    Article
  14. Observational
  15. Review
  16. Review
  17. Review
  18. Autopopulus: A Novel Framework for Autoencoder Imputation on Large Clinical Datasets.Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2021
    Article
  19. Big Data in Nephrology.Nature reviews. Nephrology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Keith C NorrisDavid Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA. KCNorris@mednet.ucla.edu.ORCID 0000-0003-3071-0700
O Kenrik DuruDavid Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Radica Z AlicicProvidence St. Joseph Health, Providence Medical Research Center, Spokane, Washington, USA.
Kenn B DarathaProvidence St. Joseph Health, Providence Medical Research Center, Spokane, Washington, USA.
Susanne B NicholasDavid Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Sterling M McPhersonProvidence St. Joseph Health, Providence Medical Research Center, Spokane, Washington, USA.
Douglas S BellDavid Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Jenny I ShenDavid Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Cami R JonesProvidence St. Joseph Health, Providence Medical Research Center, Spokane, Washington, USA.
Tannaz MoinDavid Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Amy D WatermanDavid Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Joshua J NeumillerWashington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, USA.
Roberto B VargasCharles R. Drew University of Medicine and Science, Los Angeles, USA.
Alex A T BuiDavid Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Carol M MangioneDavid Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Katherine R TuttleProvidence St. Joseph Health, Providence Medical Research Center, Spokane, Washington, USA.
CURE-CKD investigators
University of California, Los Angeles · USProvidence College · USRAND Corporation · USWashington State University Spokane · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
ConProject-002U2CDK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI KRETZLER, MATTHIAS · 2017 to 2021
$21.0M
Training Program in Clinical & Translationa Research in Human Glomerular DiseaseU54DK083912 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KRETZLER, MATTHIAS · 2009 to 2023
$20.3M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
The Center for Health Improvement of Minority ElderlyP30AG021684 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CATHERINE A SARKISIAN · 2002 to 2026
$19.7M
Transition to RecoveryP60AA026112 · NIAAA · WASHINGTON STATE UNIVERSITY · PI Denise A Dillard, Michael G McDonell · 2018 to 2026
$10.7M
Primary Outcomes in Glomerulonephritis Study (PROGRESS)UM1DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HOLZMAN, LAWRENCE B. · 2013 to 2018
$5.8M
Research Training/ Education CoreP20MD006871 · NIMHD · WASHINGTON STATE UNIVERSITY · PI BUCHWALD, DEDRA S, ROLL, JOHN M. · 2012 to 2016
$5.5M
Novel EtG BasedContingency Management for Alcohol in the Severely Mentally IllR01AA020248 · NIAAA · WASHINGTON STATE UNIVERSITY · PI MCDONELL, MICHAEL G · 2012 to 2021
$4.6M
Contingency Management Treatment of Alcohol Abuse American Indian PeopleR01AA022070 · NIAAA · WASHINGTON STATE UNIVERSITY · PI BUCHWALD, DEDRA S, MCDONELL, MICHAEL G · 2013 to 2017
$3.5M
A Cluster-Randomized Trial of Pharmacist-Coordinated Implementation of the DPPR18DK105464 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DURU, OBIDIUGWU KENRIK, MANGIONE, CAROL M · 2015 to 2019
$3.3M
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic DisordersR01EY027476 · NEI · WASHINGTON STATE UNIVERSITY · PI GIBSON, K MICHAEL · 2017 to 2020
$1.7M
ACL HHS U18DP006128CDC HHS 75D301-19-Q-69877CDC HHS U18-DP-006128NCATS NIH HHS 4UL1TR00426-10NCATS NIH HHS UL1 TR000124NEI NIH HHS R01 EY027476NIAAA NIH HHS P60 AA026112NIAAA NIH HHS R01 AA020248NIAAA NIH HHS R01 AA022070NIAAA NIH HHS R41 AA026793NIA NIH HHS P30 AG021684NIA NIH HHS R01 AG042467NIDA NIH HHS UG1 DA013714NIDDK NIH HHS K23 DK103972NIDDK NIH HHS R18 DK105464NIDDK NIH HHS U2C DK114886NIDDK NIH HHS U54 DK083912NIDDK NIH HHS UM1 DK100846NIH HHS UL1TRR001881NIMHD NIH HHS P20 MD006871NIMHD NIH HHS R01 MD014712
6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is a global public health problem, exhibiting sharp increases in incidence, prevalence, and attributable morbidity and mortality. There is a critical need to better understand the demographics, clinical characteristics, and key risk factors for CKD; and to develop platforms for testing novel interventions to improve modifiable risk factors, particularly for the CKD patients with a rapid decline in kidney function.

methodsWe describe a novel collaboration between two large healthcare systems (Providence St. Joseph Health and University of California, Los Angeles Health) supported by leadership from both institutions, which was created to develop harmonized cohorts of patients with CKD or those at increased risk for CKD (hypertension/HTN, diabetes/DM, pre-diabetes) from electronic health record data.

resultsThe combined repository of candidate records included more than 3.3 million patients with at least a single qualifying measure for CKD and/or at-risk for CKD. The CURE-CKD registry includes over 2.6 million patients with and/or at-risk for CKD identified by stricter guide-line based criteria using a combination of administrative encounter codes, physical examinations, laboratory values and medication use. Notably, data based on race/ethnicity and geography in part, will enable robust analyses to study traditionally disadvantaged or marginalized patients not typically included in clinical trials. DISCUSSION: CURE-CKD project is a unique multidisciplinary collaboration between nephrologists, endocrinologists, primary care physicians with health services research skills, health economists, and those with expertise in statistics, bio-informatics and machine learning. The CURE-CKD registry uses curated observations from real-world settings across two large healthcare systems and has great potential to provide important contributions for healthcare and for improving clinical outcomes in patients with and at-risk for CKD.

Indexed as

Comprehensive Health CareElectronic Health RecordsRenal Insufficiency, ChronicAdultDiabetes MellitusDisease ProgressionFemaleHumansHypertensionMaleMedical Record LinkagePrevalencePrognosisQuality ImprovementRegistriesRisk AssessmentChronic kidney diseaseDiabetesElectronic health recordsHealthcare systemsHypertensionPre-diabetesRegistryStudy design

Identifiers

PMID31747918
PMCPMC6868861
OpenAlexW2989861528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.